Prosecution Insights
Last updated: April 19, 2026

Examiner: ADLAM, CHANTAL PETA-GAYE

Tech Center 1600 • Art Units: 1622 1625

This examiner grants 49% of resolved cases

Performance Statistics

49.1%
Allow Rate
-10.9% vs TC avg
86
Total Applications
+24.2%
Interview Lift
1339
Avg Prosecution Days
Based on 55 resolved cases, 2023–2026

Rejection Statute Breakdown

2.5%
§101 Eligibility
12.7%
§102 Novelty
36.3%
§103 Obviousness
20.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17689286 Methods of treating cancer using a combination of SERD Dosing Regimens Non-Final OA Eli Lilly and Company
17623246 NTRANASAL DANTROLENE ADMINISTRATION FOR TREATMENT OF ALZHEIMER'S DISEASE Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17799149 COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING OCULAR DISORDERS Final Rejection University of Virginia Patent Foundation
18004997 ANTIPERSPIRANT STICK COMPOSITIONS Non-Final OA Conopco, Inc., d/b/a UNILEVER
17040011 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES Final Rejection ETH ZURICH
17903138 COVID-19 THERAPEUTICS AND METHODS OF TREATMENT Final Rejection Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
17418518 PHARMACEUTICAL COMPOSITION Non-Final OA KOWA COMPANY, LTD.
17874928 FEED ADDITIVE FOR IMPROVING PERFORMANCE OF DOMESTICATED ANIMALS Non-Final OA PMI Nutrition, LLC
17286797 TREATMENT OF NEUROLOGICAL DISEASE Non-Final OA The University of Sheffield
17436010 MEDIUM CHAIN TRIGLYCERIDE FORMULATIONS WITH IMPROVED BIOAVAILABILITY AND METHODS RELATED THERETO Non-Final OA Cerecin Inc.
17295162 COMPOUNDS FOR PHOTODYNAMIC THERAPY AND RELATED USES Non-Final OA GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
18462388 APPLICATION OF CHANNEL BLOCKER IN PREPARATION OF DRUGS FOR TREATING AND/OR PREVENTING LIVER FIBROSIS Non-Final OA Affiliated Hospital of Zunyi Medical University
17949754 N-PALMITOYLETHANOLAMIDE AND DOCOSAHEXAENOIC ACID FOR USE IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND OTHER DEPRESSIVE SYNDROMES Non-Final OA EPITECH GROUP S.P.A.
17941531 NITRATED PSILOCYBIN DERIVATIVES AND METHODS OF USING Non-Final OA Enveric Biosciences Canada Inc.
17801434 Compositions and Methods for Treatment of Cytokine Storm and Cytokine Release Syndrome Final Rejection Yinuoke Medicine Science Technology Company Ltd.
17830073 TREATING COGNITIVE DISORDERS USING TRAPIDIL Final Rejection Sinopia Biosciences, Inc.
17775269 TOPICAL DELIVERY OF TOFACITINIB USING IONIC LIQUID Non-Final OA CAGE BIO, INC.
17760644 COMBINATION TREATMENT WITH A P53 REACTIVATOR AND AN INHIBITOR OF AN ANTIAPOPTOTIC BCL-2 FAMILY PROTEIN Non-Final OA Aprea Therapeutics AB
17597462 TRANSDERMAL PERMEATION ENHANCING COMPOSITION AND APPLICATION THEREOF IN TIMOLOL PREPARATION Non-Final OA WUHAN CONFORM PHARMACEUTICAL CO., LTD.
17078255 METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS Final Rejection BIOMED VALLEY DISCOVERIES, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month